The multiple sclerosis treatment began with the approval of IFN-β and glatiramer acetate, then the first monoclonal antibody natalizumab, followed by oral medications (fingolimod, teriflunomide, dimethyl fumarate, and cladribine). This evidence concerns the gene IFNB1 and multiple sclerosis.